» Articles » PMID: 19623177

MLH1 Mediates PARP-dependent Cell Death in Response to the Methylating Agent N-methyl-N-nitrosourea

Overview
Journal Br J Cancer
Specialty Oncology
Date 2009 Jul 23
PMID 19623177
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Methylating agents such as N-methyl-N-nitrosourea (MNU) can cause cell cycle arrest and death either via caspase-dependent apoptosis or via a poly(ADP-ribose) polymerase (PARP)-dependent form of apoptosis. We wished to investigate the possible role of MLH1 in signalling cell death through PARP.

Methods: Fibroblasts are particularly dependent on a PARP-mediated cell death response to methylating agents. We used hTERT-immortalised normal human fibroblasts (WT) to generate isogenic MLH1-depleted cells, confirmed by quantitative PCR and western blotting. Drug resistance was measured by clonogenic and cell viability assays and effects on the cell cycle by cell sorting. Damage signalling was additionally investigated using immunostaining.

Results: MLH1-depleted cells were more resistant to MNU, as expected. Despite having an intact G(2)/M checkpoint, the WT cells did not initially undergo cell cycle arrest but instead triggered cell death directly by PARP overactivation and nuclear translocation of apoptosis-inducing factor (AIF). The MLH1-depleted cells showed defects in this pathway, with decreased staining for phosphorylated H2AX, altered PARP activity and reduced AIF translocation. Inhibitors of PARP, but not of caspases, blocked AIF translocation and greatly decreased short-term cell death in both WT and MLH1-depleted cells. This MLH1-dependent response to MNU was not blocked by inhibitors of ATM/ATR or p53.

Conclusion: These novel data indicate an important role for MLH1 in signalling PARP-dependent cell death in response to the methylating agent MNU.

Citing Articles

Prime Editing and DNA Repair System: Balancing Efficiency with Safety.

Daliri K, Hescheler J, Pfannkuche K Cells. 2024; 13(10.

PMID: 38786078 PMC: 11120019. DOI: 10.3390/cells13100858.


The UHRF1 protein is a key regulator of retrotransposable elements and innate immune response to viral RNA in human cells.

Irwin R, Scullion C, Thursby S, Sun M, Thakur A, Hilman L Epigenetics. 2023; 18(1):2216005.

PMID: 37246786 PMC: 10228402. DOI: 10.1080/15592294.2023.2216005.


as an Emerging Predictive Biomarker in Ovarian Cancer.

Hutchcraft M, Gallion H, Kolesar J Diagnostics (Basel). 2021; 11(1).

PMID: 33419231 PMC: 7825630. DOI: 10.3390/diagnostics11010084.


Promoter Methylation and Prediction/Prognosis of Gastric Cancer: A Systematic Review and Meta and Bioinformatic Analysis.

Shen S, Chen X, Li H, Sun L, Yuan Y J Cancer. 2018; 9(11):1932-1942.

PMID: 29896277 PMC: 5995951. DOI: 10.7150/jca.23284.


The clinicopathological significance of hMLH1 hypermethylation in non-small-cell lung cancer: a meta-analysis and literature review.

Han Y, Shi K, Zhou S, Yu D, Liu Z Onco Targets Ther. 2016; 9:5081-90.

PMID: 27574449 PMC: 4993409. DOI: 10.2147/OTT.S106345.


References
1.
Tentori L, Turriziani M, Franco D, Serafino A, Levati L, Roy R . Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia. 1999; 13(6):901-9. DOI: 10.1038/sj.leu.2401423. View

2.
Peterson-Roth E, Reynolds M, Quievryn G, Zhitkovich A . Mismatch repair proteins are activators of toxic responses to chromium-DNA damage. Mol Cell Biol. 2005; 25(9):3596-607. PMC: 1084304. DOI: 10.1128/MCB.25.9.3596-3607.2005. View

3.
Roques C, Boyer J, Farber R . Microsatellite mutation rates are equivalent in normal and telomerase-immortalized human fibroblasts. Cancer Res. 2001; 61(23):8405-7. View

4.
Milam K, Thomas G, Cleaver J . Disturbances in DNA precursor metabolism associated with exposure to an inhibitor of poly(ADP-ribose) synthetase. Exp Cell Res. 1986; 165(1):260-8. DOI: 10.1016/0014-4827(86)90550-1. View

5.
Yanamadala S, Ljungman M . Potential role of MLH1 in the induction of p53 and apoptosis by blocking transcription on damaged DNA templates. Mol Cancer Res. 2003; 1(10):747-54. View